Who Supplies Secnidazole to India from FRANCE

Importing finished pharmaceutical formulations containing Secnidazole into India requires compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations. The importing company must obtain a valid Importer License from the Directorate General of Foreign Trade (DGFT). Each product must be registered with CDSCO, which involves submitting Form 40 or 41, depending on the product's nature. The registration process includes providing a Certificate of Pharmaceutical Product (CoPP), manufacturing license, and stability data. The timeline for import drug registration varies but typically ranges from 6 to 12 months. For Secnidazole formulations under HS Code 30049024, specific requirements include demonstrating compliance with the Indian Pharmacopoeia standards and providing a No Objection Certificate (NOC) from the manufacturer.

Imported Secnidazole formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to International Council for Harmonisation (ICH) Zone IV guidelines, must be provided to ensure product efficacy and safety. Port inspections by customs drug inspectors are mandatory to verify the authenticity and quality of the imported products.

Between 2024 and 2026, CDSCO has implemented stricter regulations for importing finished pharmaceutical formulations, including Secnidazole. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially affecting the volume of imports. Bilateral agreements between India and France have facilitated smoother trade processes, but compliance with updated regulatory standards remains essential.

India imports finished Secnidazole formulations to meet the demand for specific dosage forms not produced domestically, such as certain tablet strengths and combination therapies. The market size for Secnidazole formulations in India is substantial, with a total export market of $30.3 million across 115 exporters to 77 countries. Domestic production may not fully satisfy the demand for these specialized formulations, leading to reliance on imports.

The Basic Customs Duty (BCD) for Secnidazole formulations under HS Code 30049024 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is levied on the BCD. Integrated Goods and Services Tax (IGST) is applicable, with the rate varying based on the product's classification. Anti-dumping duties and exemptions may apply depending on the country of origin and prevailing trade policies. The total landed duty percentage is calculated by summing the BCD, SWS, and IGST.

India sources Secnidazole formulations from France due to the availability of patented or specialized formulations not produced domestically. French manufacturers offer high-quality products that meet international standards, providing a competitive advantage in terms of efficacy and safety. Other suppliers, such as China, Germany, and the United States, also export Secnidazole formulations to India, but France's reputation for quality and innovation positions it favorably in the Indian market.

India imports Secnidazole formulations from France to access patented or specialized dosage forms not available domestically. French manufacturers provide high-quality products that meet international standards, ensuring efficacy and safety. The availability of these specialized formulations in France addresses specific therapeutic needs in the Indian market.

Compared to other origins like China, Germany, and the United States, France offers Secnidazole formulations with superior quality and compliance with international standards. While other countries may offer competitive pricing, France's reputation for quality and innovation provides a unique advantage in the Indian market.

Potential risks for Indian importers include reliance on a single source, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have been minimal, but it's essential to monitor the supply chain continuously.

1. 1Dual-Sourcing: Engage multiple suppliers to mitigate supply chain risks.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against potential disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letter of Credit (LC) or Documents Against Payment (DA/DP).
4. 4Minimum Order Quantities (MOQs): Align order sizes with demand forecasts to optimize inventory.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance.

1. 1DGFT Importer Exporter Code (IEC): Obtain a valid IEC from DGFT.
2. 2CDSCO Form 40/41: Submit the appropriate form for product registration.
3. 3Drug Import License: Secure a license for importing pharmaceutical products.
4. 4No Objection Certificate (NOC): Obtain NOC from the manufacturer.
5. 5Customs Broker: Engage a licensed customs house agent for clearance.
6. 6Advance Ruling: Seek classification and duty determination from CBIC.

1. 1Certificate of Analysis (CoA): Confirming product quality and compliance.
2. 2Certificate of Pharmaceutical Product (CoPP): Indicating regulatory approval.
3. 3Good Manufacturing Practice (GMP) Certificate: Ensuring manufacturing standards.
4. 4Drug Master File (DMF): Providing detailed product information.
5. 5Stability Data: